295 related articles for article (PubMed ID: 26762172)
1. Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase.
Pala D; Rivara S; Mor M; Milazzo FM; Roscilli G; Pavoni E; Giannini G
Glycobiology; 2016 Jun; 26(6):640-54. PubMed ID: 26762172
[TBL] [Abstract][Full Text] [Related]
2. Roneparstat: Development, Preclinical and Clinical Studies.
Noseda A; Barbieri P
Adv Exp Med Biol; 2020; 1221():523-538. PubMed ID: 32274725
[TBL] [Abstract][Full Text] [Related]
3. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).
Gandhi NS; Freeman C; Parish CR; Mancera RL
Glycobiology; 2012 Jan; 22(1):35-55. PubMed ID: 21746763
[TBL] [Abstract][Full Text] [Related]
4. Investigating Glycol-Split-Heparin-Derived Inhibitors of Heparanase: A Study of Synthetic Trisaccharides.
Ni M; Elli S; Naggi A; Guerrini M; Torri G; Petitou M
Molecules; 2016 Nov; 21(11):. PubMed ID: 27886097
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.
Cassinelli G; Favini E; Dal Bo L; Tortoreto M; De Maglie M; Dagrada G; Pilotti S; Zunino F; Zaffaroni N; Lanzi C
Oncotarget; 2016 Jul; 7(30):47848-47863. PubMed ID: 27374103
[TBL] [Abstract][Full Text] [Related]
6. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
Zhou Z; Bates M; Madura JD
Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
8. Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat.
Alekseeva A; Mazzini G; Giannini G; Naggi A
Carbohydr Polym; 2017 Jan; 156():470-480. PubMed ID: 27842848
[TBL] [Abstract][Full Text] [Related]
9. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.
Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y
Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of heparin/heparan sulfate binding domains of the endoglycosidase heparanase.
Levy-Adam F; Abboud-Jarrous G; Guerrini M; Beccati D; Vlodavsky I; Ilan N
J Biol Chem; 2005 May; 280(21):20457-66. PubMed ID: 15760902
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
12. Molecular Aspects of Heparanase Interaction with Heparan Sulfate, Heparin and Glycol Split Heparin.
Elli S; Guerrini M
Adv Exp Med Biol; 2020; 1221():169-188. PubMed ID: 32274710
[TBL] [Abstract][Full Text] [Related]
13. Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.
Xiang J; Lu M; Shi M; Cheng X; Kwakwa KA; Davis JL; Su X; Bakewell SJ; Zhang Y; Fontana F; Xu Y; Veis DJ; DiPersio JF; Ratner L; Sanderson RD; Noseda A; Mollah S; Li J; Weilbaecher KN
J Virol; 2022 Apr; 96(7):e0005722. PubMed ID: 35319225
[TBL] [Abstract][Full Text] [Related]
14. Processing of macromolecular heparin by heparanase.
Gong F; Jemth P; Escobar Galvis ML; Vlodavsky I; Horner A; Lindahl U; Li JP
J Biol Chem; 2003 Sep; 278(37):35152-8. PubMed ID: 12837765
[TBL] [Abstract][Full Text] [Related]
15. Molecular model of human heparanase with proposed binding mode of a heparan sulfate oligosaccharide and catalytic amino acids.
Sapay N; Cabannes E; Petitou M; Imberty A
Biopolymers; 2012 Jan; 97(1):21-34. PubMed ID: 21780097
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and evaluation of heparan sulfate mimicking glycopolymers for inhibiting heparanase activity.
Loka RS; Yu F; Sletten ET; Nguyen HM
Chem Commun (Camb); 2017 Aug; 53(65):9163-9166. PubMed ID: 28766595
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical and clinical significance of heparanase in Ewing's sarcoma.
Shafat I; Ben-Arush MW; Issakov J; Meller I; Naroditsky I; Tortoreto M; Cassinelli G; Lanzi C; Pisano C; Ilan N; Vlodavsky I; Zunino F
J Cell Mol Med; 2011 Sep; 15(9):1857-64. PubMed ID: 21029368
[TBL] [Abstract][Full Text] [Related]
18. Polymeric fluorescent heparin as one-step FRET substrate of human heparanase.
Sistla JC; Morla S; Alabbas AB; Kalathur RC; Sharon C; Patel BB; Desai UR
Carbohydr Polym; 2019 Feb; 205():385-391. PubMed ID: 30446119
[TBL] [Abstract][Full Text] [Related]
19. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase.
Wilson JC; Laloo AE; Singh S; Ferro V
Biochem Biophys Res Commun; 2014 Jan; 443(1):185-8. PubMed ID: 24291708
[TBL] [Abstract][Full Text] [Related]
20. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.
Vlodavsky I; Ilan N; Naggi A; Casu B
Curr Pharm Des; 2007; 13(20):2057-73. PubMed ID: 17627539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
